JPS62501263A - 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体 - Google Patents
脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体Info
- Publication number
- JPS62501263A JPS62501263A JP61500204A JP50020485A JPS62501263A JP S62501263 A JPS62501263 A JP S62501263A JP 61500204 A JP61500204 A JP 61500204A JP 50020485 A JP50020485 A JP 50020485A JP S62501263 A JPS62501263 A JP S62501263A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- glycoprotein
- antibody
- polypeptide
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000288 Glycoproteins Proteins 0.000 title claims description 93
- 102000003886 Glycoproteins Human genes 0.000 title claims description 93
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 61
- 229920001184 polypeptide Polymers 0.000 title claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 58
- 230000003612 virological effect Effects 0.000 title claims description 17
- 241000700605 Viruses Species 0.000 claims description 84
- 210000002966 serum Anatomy 0.000 claims description 51
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 210000004779 membrane envelope Anatomy 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 241001430294 unidentified retrovirus Species 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 230000003053 immunization Effects 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000010790 dilution Methods 0.000 claims description 15
- 239000012895 dilution Substances 0.000 claims description 15
- 239000002054 inoculum Substances 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 238000002649 immunization Methods 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 13
- 230000009257 reactivity Effects 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 11
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 10
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000016784 immunoglobulin production Effects 0.000 claims description 8
- 101710091045 Envelope protein Proteins 0.000 claims description 7
- 101710154606 Hemagglutinin Proteins 0.000 claims description 7
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 7
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 7
- 101710176177 Protein A56 Proteins 0.000 claims description 7
- 101710188315 Protein X Proteins 0.000 claims description 7
- 241000714223 Rauscher murine leukemia virus Species 0.000 claims description 7
- 230000009260 cross reactivity Effects 0.000 claims description 7
- 239000000185 hemagglutinin Substances 0.000 claims description 7
- 230000004988 N-glycosylation Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 4
- 125000000837 carbohydrate group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000003147 glycosyl group Chemical group 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000010154 cross-pollination Effects 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims 6
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims 6
- 241000714165 Feline leukemia virus Species 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 102100021696 Syncytin-1 Human genes 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 claims 1
- 241000714177 Murine leukemia virus Species 0.000 claims 1
- 208000005074 Retroviridae Infections Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 8
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 8
- 101800001271 Surface protein Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000022811 deglycosylation Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101500013890 Friend murine leukemia virus Surface protein Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67600884A | 1984-11-29 | 1984-11-29 | |
| US676008 | 1984-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62501263A true JPS62501263A (ja) | 1987-05-21 |
Family
ID=24712837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61500204A Pending JPS62501263A (ja) | 1984-11-29 | 1985-11-20 | 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0203177A4 (fr) |
| JP (1) | JPS62501263A (fr) |
| WO (1) | WO1986003224A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2590674B1 (fr) * | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
| DK155886D0 (da) * | 1986-04-04 | 1986-04-04 | Bo Arne Hofmann | Vaccine og fremgangsmaade til fremstilling af denne |
| US5352449A (en) * | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
| WO1987007301A1 (fr) * | 1986-05-30 | 1987-12-03 | Cambridge Bioscience Corporation | Procede pour preparer et utiliser des antigenes du virus de la leucemie feline |
| ES2299276T3 (es) | 1998-12-31 | 2008-05-16 | Novartis Vaccines And Diagnostics, Inc. | Polipeptidos env del vih modificados. |
| CA2360347C (fr) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Expression amelioree de polypeptides hiv et production de particules de type viral |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| EP1427806A4 (fr) | 2001-08-31 | 2006-04-26 | Chiron Corp | Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations |
| CA2615372A1 (fr) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Particules semblables au virus grippal a comprenant de l'hemagglutinine |
| CN101978066A (zh) | 2007-11-27 | 2011-02-16 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
| PT2294202E (pt) | 2008-07-08 | 2015-10-09 | Medicago Inc | Antigénios gripais recombinantes solúveis |
| ES2593277T3 (es) | 2008-07-18 | 2016-12-07 | Medicago Inc. | Nuevo epítopo de inmunización contra el virus de la influenza |
| ES2784189T3 (es) | 2009-03-27 | 2020-09-23 | Academia Sinica | Métodos y composiciones para la inmunización contra virus |
| NZ597401A (en) | 2009-06-24 | 2013-09-27 | Medicago Inc | Chimeric influenza virus-like particles comprising hemagglutinin |
| PL2480658T3 (pl) | 2009-09-22 | 2017-12-29 | Medicago Inc. | Sposób otrzymywania VLP pochodzenia roślinnego |
| TWI537385B (zh) | 2010-11-04 | 2016-06-11 | 中央研究院 | 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法 |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5463849A (en) * | 1977-10-31 | 1979-05-23 | Seiko Epson Corp | Eyeglass frame |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984004327A1 (fr) * | 1983-04-27 | 1984-11-08 | Harvard College | Procede et produits de detection du virus de la leucemie de cellules t humaines |
| US4701416A (en) * | 1983-12-09 | 1987-10-20 | Cetus Corporation | Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV |
| US4724258A (en) * | 1984-02-03 | 1988-02-09 | Juridical Foundation, Japanese Foundation For Cancer Research | Adult T cell leukemia virus antigen polypeptide |
| DK171119B1 (da) * | 1985-04-19 | 1996-06-17 | Hoffmann La Roche | AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin |
-
1985
- 1985-11-20 JP JP61500204A patent/JPS62501263A/ja active Pending
- 1985-11-20 EP EP19860900378 patent/EP0203177A4/fr not_active Withdrawn
- 1985-11-20 WO PCT/US1985/002319 patent/WO1986003224A1/fr not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5463849A (en) * | 1977-10-31 | 1979-05-23 | Seiko Epson Corp | Eyeglass frame |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0203177A1 (fr) | 1986-12-03 |
| EP0203177A4 (fr) | 1987-04-28 |
| WO1986003224A1 (fr) | 1986-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS62501263A (ja) | 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体 | |
| Osterhaus et al. | Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. | |
| JPS62277400A (ja) | Ｈｔｌｖ−３エンベロ−プ蛋白質 | |
| JPS62224293A (ja) | コクシジウム症予防用抗原性蛋白質およびそれを含有するワクチン | |
| CA2268372A1 (fr) | Compositions et procedes destines au traitement d'infections virales | |
| UA72199C2 (en) | VACCINE CONTAINING AT LEAST ONE PARTICULATE IMMUNOGEN AND ADJUVANTING AMOUNT OF SUBUNITS OF e. COLI HEAT-LABILE ENTEROTOXIN (LTB) FREE FROM CONTAMINATING A SUBUNITS OR TOXIC HOLOTOXIN, ITS USE FOR INDUCTION OF LOCAL AND SYSTEMIC PROTECTIVE RESPONSE AGAINST PARTICULATE IMMUNOGEN UPON MUCOSAL ADMINISTRATION | |
| Nascimento et al. | Effective immune protection of pigs against cysticercosis | |
| Schäfer et al. | Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms | |
| EP0291636A1 (fr) | Réponse immunitaire aux virus induits par des anticorps anti-idiotype | |
| DE3855869D1 (de) | Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern | |
| IE60671B1 (en) | Monoclonal antiobodies to HIV and related peptides | |
| CN100381463C (zh) | 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途 | |
| Fisher et al. | Specific T-cell response to a Pneumocystis carinii surface glycoprotein (gp120) after immunization and natural infection | |
| JPH07506810A (ja) | 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用 | |
| JP2616915B2 (ja) | 中和糖タンパク質のペプチド | |
| GB2031433A (en) | Modification of the quercitin moiety of timothy grass pollen antigens or fragments thereof | |
| Pearce et al. | Three major surface antigens of Schistosoma mansoni are linked to the membrane by glycosylphosphatidylinositol. | |
| Traavik et al. | California encephalitis group viruses isolated from mosquitoes collected in Southern and Arctic Norway | |
| Smith et al. | Evidence of separate pathways for viral and chemical carcinogenesis in C3H/StWi mouse mammary glands | |
| US5658569A (en) | Anti-HIV-1 neutralizing antibodies | |
| Ihle et al. | Characterization of the immune response to the major glycoprotein (gp71) of friend leukemia virus II. Response in C57BL/6 mice | |
| US6093400A (en) | Modified HGP-30 peptides, conjugates, compositions and methods of use | |
| JPH04507409A (ja) | 風疹ｅ１ペプチド | |
| AU733234B2 (en) | Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders | |
| CN1082053A (zh) | 合成多肽 |